A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects with Cystic Fibrosis and the G551D Mutation

Grants and Contracts Details

StatusFinished
Effective start/end date8/26/09 → 8/25/10

Funding

  • Vertex Pharmaceuticals Inc: $3,465.00